Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar 27:9:4.
doi: 10.1186/s40164-020-00161-7. eCollection 2020.

Clinical implications of recurrent gene mutations in acute myeloid leukemia

Jifeng Yu #  1   2 , Yingmei Li #  1 , Danfeng Zhang  1 , Dingming Wan  1 , Zhongxing Jiang  1
Affiliations
Review

Clinical implications of recurrent gene mutations in acute myeloid leukemia

Jifeng Yu et al. Exp Hematol Oncol. .

Abstract

Acute myeloid leukemia (AML) is a genetically heterogeneous clonal malignancy characterized by recurrent gene mutations. Genomic heterogeneity, patients' individual variability, and recurrent gene mutations are the major obstacles among many factors that impact treatment efficacy of the AML patients. With the application of cost- and time-effective next-generation sequencing (NGS) technologies, an enormous diversity of genetic mutations has been identified. The recurrent gene mutations and their important roles in acute myeloid leukemia (AML) pathogenesis have been studied extensively. In this review, we summarize the recent development on the gene mutation in patients with AML.

Keywords: ASXL1; Acute myeloid leukemia (AML); CEBPA; FLT3; IDH1/2; NPM1; RUNX1; Recurrent gene mutation; TP53.

PubMed Disclaimer

Conflict of interest statement

Competing interestsThe authors declare that they have no competing interests.

References

    1. Chen J, Odenike O, Rowley JD. Leukaemogenesis: more than mutant genes. Nat Rev Cancer. 2010;10(1):23–36. - PMC - PubMed
    1. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. - PMC - PubMed
    1. Yu J, Li Y, Li T, Li Y, Xing H, Sun H, et al. Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia. Exp Hematol Oncol. 2020;6(9):2. - PMC - PubMed
    1. Han X, Li W, He N, Feng P, Pang Y, Ji C, et al. Gene mutation patterns of Chinese acute myeloid leukemia patients by targeted next-generation sequencing and bioinformatic analysis. Clin Chim Acta. 2018;479:25–37. - PubMed
    1. Chung W, Kelly AD, Kropf P, Fung H, Jelinek J, Su XY, et al. Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia. Clin Epigenet. 2019;11(1):106. - PMC - PubMed